首页> 外文期刊>Pathology oncology research: POR >Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma
【24h】

Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma

机译:Ki-67和细胞周期调节剂p53,p63和cyclinD1作为膀胱尿路上皮癌复发/进展的预后标志物

获取原文
获取外文期刊封面目录资料

摘要

Deregulation of the cell cycle regulating genes is common in urothelial bladder carcinoma (UBC). We aimed to examine the prognostic significance of ki-67, p53, p63 and cyclinD1expression in UBC and to identify optimal cut-off points to help identifying patients at high risk of tumor recurrence. We evaluated the immunohistochemical expression of ki-67, p53, p63 and cyclinD1 in 100 UBCs. The conventional and the classification and regression trees-guided (CART-guided) methods were utilized to determine the independent predictors of tumor recurrence. The p53 and Ki-67 expression didna??t associate significantly with tumor recurrence.p63 and cyclinD1 exhibited significant hazard ratios. Using CART, no recurrence was observed when p63 was a?¥87.5%. The recurrence incidence increased and the disease free survival (DFS) time shortened as the p63 decreased. CyclinD1 associated significantly with tumor recurrence only if p63 was 35%. Using the CART cut-off values??, cases were categorized into three groups; (groups I: p63??a?¥??35%, II: p63????35% and cyclinD1????10% and III: p63????35% and cyclinD1??a?¥??10%). Group I patients revealed the least incidence of recurrence at the longest DFS. Group III had the worst prognosis followed by Group II. p63 represents a surrogant biomarker to predict UBC recurrence.CyclinD1 can be used only when p63 is 35%. CART proved helpful with data among which the number of cases with positive outcomes is too small relative to the number of studied predictors. Large cohort studies for ki-67 and p53 are recommended to be performed with standardized criteria as regards patientsa?? characteristics, cut-off values, and follow-up time.
机译:细胞周期调节基因的失调在尿路上皮膀胱癌(UBC)中很常见。我们旨在检查UBC中ki-67,p53,p63和cyclinD1表达的预后意义,并确定最佳分界点,以帮助鉴定高肿瘤复发风险的患者。我们评估了100个UBC中ki-67,p53,p63和cyclinD1的免疫组织化学表达。常规方法以及分类和回归树指导(CART指导)方法用于确定肿瘤复发的独立预测因子。 p53和Ki-67的表达与肿瘤的复发没有显着相关。p63和cyclinD1显示出显着的危险比。使用CART,当p63为¥ 87.5%时,未观察到复发。随着p63的减少,复发率增加,无病生存(DFS)时间缩短。仅当p63 <35%时,CyclinD1才与肿瘤复发显着相关。使用CART截止值?,将病例分为三组: (组I:p63Δα≥35%,II:p63α<Δ35%和cyclinD1α<α10%,III:p63α<Δ35%和cyclinD1αα。 ?¥ ?? 10%)。 I组患者在DFS最长的时间显示复发率最低。第三组的预后最差,第二组紧随其后。 p63代表预测UBC复发的替代生物标志物。CyclinD1仅可在p63 <35%时使用。事实证明,CART可以帮助获得阳性结果的病例数相对于所研究预测因素的数目太少的数据。对于ki-67和p53的大型队列研究,建议按照关于患者的标准化标准进行。特征,临界值和随访时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号